TY - JOUR A1 - Bárcena-Uribarri, Iván A1 - Thein, Marcus A1 - Maier, Elke A1 - Bonde, Mari A1 - Bergström, Sven A1 - Benz, Roland T1 - Use of Nonelectrolytes Reveals the Channel Size and Oligomeric Constitution of the Borrelia burgdorferi P66 Porin JF - PLoS ONE N2 - In the Lyme disease spirochete Borrelia burgdorferi, the outer membrane protein P66 is capable of pore formation with an atypical high single-channel conductance of 11 nS in 1 M KCl, which suggested that it could have a larger diameter than ‘normal’ Gram-negative bacterial porins. We studied the diameter of the P66 channel by analyzing its single-channel conductance in black lipid bilayers in the presence of different nonelectrolytes with known hydrodynamic radii. We calculated the filling of the channel with these nonelectrolytes and the results suggested that nonelectrolytes (NEs) with hydrodynamic radii of 0.34 nm or smaller pass through the pore, whereas neutral molecules with greater radii only partially filled the channel or were not able to enter it at all. The diameter of the entrance of the P66 channel was determined to be \(\leq\)1.9 nm and the channel has a central constriction of about 0.8 nm. The size of the channel appeared to be symmetrical as judged from one-sidedness of addition of NEs. Furthermore, the P66-induced membrane conductance could be blocked by 80–90% by the addition of the nonelectrolytes PEG 400, PEG 600 and maltohexaose to the aqueous phase in the low millimolar range. The analysis of the power density spectra of ion current through P66 after blockage with these NEs revealed no chemical reaction responsible for channel block. Interestingly, the blockage of the single-channel conductance of P66 by these NEs occurred in about eight subconductance states, indicating that the P66 channel could be an oligomer of about eight individual channels. The organization of P66 as a possible octamer was confirmed by Blue Native PAGE and immunoblot analysis, which both demonstrated that P66 forms a complex with a mass of approximately 460 kDa. Two dimension SDS PAGE revealed that P66 is the only polypeptide in the complex. KW - radii KW - hydrodynamics KW - SDS polyacrylamide gel electrophoresis KW - molecular mass KW - outer membrane proteins KW - single channel recording KW - blue native polyacrylamide gel electrophoresis KW - borrelia burgdorferi Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-129965 VL - 8 IS - 11 ER - TY - JOUR A1 - Prelog, Martina T1 - Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies JF - Clinical & Cellular Immunology N2 - Patients with rheumatoid arthritis (RA) are at higher risk to suffer from morbidity due to vaccine-preventable diseases and, thus, display an important target population to receive vaccines for protection from infectious complications. There have been only a few studies focusing on the administration of vaccines in RA patients with immunotherapy. Overall, antibody response rates against influenza or pneumococcal disease appeared to be only slightly lower than expected in healthy individuals. Crucial problems in the interpretation of data from studies in RA patients vaccinated against influenza and pneumococcal disease are the impaired comparability of studies due to different study designs and type of vaccines used, different health states among RA patients, heterogeneity in treatments including concomitant therapy with conventional DMARDs and glucocorticoids in addition to biological agents. Assessment of vaccination status should be performed in the initial work-up of patients with RA and should ideally be administered before initiation of immunotherapies or during stable disease. Due to differences in antibody responses and uncertainty regarding maintenance of protective antibodies, routine controls for antibody titers and specific strategies for earlier re-vaccination might be scheduled for patients with RA. KW - Immunotherapy KW - Anti-TNF-alpha agents KW - Rituximab KW - Tocilizumab KW - Abatacept KW - Pneumococcal vaccination KW - Influenza vaccination Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-96446 ER - TY - JOUR A1 - Duggal, Rohit A1 - Geissinger, Ulrike A1 - Zhang, Qian A1 - Aguilar, Jason A1 - Chen, Nanhai G. A1 - Binda, Elena A1 - Vescovi, Angelo L. A1 - Szalay, Aladar A. T1 - Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival JF - Journal of Translational Medicine N2 - No abstract availableBackground: Glioblastoma multiforme (GBM) is one of the most aggressive forms of cancer with a high rate of recurrence. We propose a novel oncolytic vaccinia virus (VACV)-based therapy using expression of the bone morphogenetic protein (BMP)-4 for treating GBM and preventing recurrence. Methods: We have utilized clinically relevant, orthotopic xenograft models of GBM based on tumor-biopsy derived, primary cancer stem cell (CSC) lines. One of the cell lines, after being transduced with a cDNA encoding firefly luciferase, could be used for real time tumor imaging. A VACV that expresses BMP-4 was constructed and utilized for infecting several primary glioma cultures besides conventional serum-grown glioma cell lines. This virus was also delivered intracranially upon implantation of the GBM CSCs in mice to determine effects on tumor growth. Results: We found that the VACV that overexpresses BMP-4 demonstrated heightened replication and cytotoxic activity in GBM CSC cultures with a broad spectrum of activity across several different patient-biopsy cultures. Intracranial inoculation of mice with this virus resulted in a tumor size equal to or below that at the time of injection. This resulted in survival of 100% of the treated mice up to 84 days post inoculation, significantly superior to that of a VACV lacking BMP-4 expression. When mice with a higher tumor burden were injected with the VACV lacking BMP-4, 80% of the mice showed tumor recurrence. In contrast, no recurrence was seen when mice were injected with the VACV expressing BMP-4, possibly due to induction of differentiation in the CSC population and subsequently serving as a better host for VACV infection and oncolysis. This lack of recurrence resulted in superior survival in the BMP-4 VACV treated group. Conclusions: Based on these findings we propose a novel VACV therapy for treating GBM, which would allow tumor specific production of drugs in the future in combination with BMPs which would simultaneously control tumor maintenance and facilitate CSC differentiation, respectively, thereby causing sustained tumor regression without recurrence. KW - cancer stem cells (CSCs) and differentiation KW - glioblastoma multiforme (GBM) KW - vaccinia virus (VACV) KW - bone morphogenetic protein (BMP) Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-129626 VL - 11 IS - 155 ER - TY - JOUR A1 - Gholami, Sepideh A1 - Chen, Chun-Hao A1 - Belin, Laurence J. A1 - Lou, Emil A1 - Fujisawa, Sho A1 - Antonacci, Caroline A1 - Carew, Amanda A1 - Chen, Nanhai G. A1 - De Brot, Marina A1 - Zanzonico, Pat B. A1 - Szalay, Aladar A. A1 - Fong, Yuman T1 - Vaccinia virus GLV-1h153 is a novel agent for detection and effective local control of positive surgical margins for breast cancer JF - Breast Cancer Research N2 - Introduction: Surgery is currently the definitive treatment for early-stage breast cancer. However, the rate of positive surgical margins remains unacceptably high. The human sodium iodide symporter (hNIS) is a naturally occurring protein in human thyroid tissue, which enables cells to concentrate radionuclides. The hNIS has been exploited to image and treat thyroid cancer. We therefore investigated the potential of a novel oncolytic vaccinia virus GLV1h-153 engineered to express the hNIS gene for identifying positive surgical margins after tumor resection via positron emission tomography (PET). Furthermore, we studied its role as an adjuvant therapeutic agent in achieving local control of remaining tumors in an orthotopic breast cancer model. Methods: GLV-1h153, a replication-competent vaccinia virus, was tested against breast cancer cell lines at various multiplicities of infection (MOIs). Cytotoxicity and viral replication were determined. Mammary fat pad tumors were generated in athymic nude mice. To determine the utility of GLV-1h153 in identifying positive surgical margins, 90% of the mammary fat pad tumors were surgically resected and subsequently injected with GLV-1h153 or phosphate buffered saline (PBS) in the surgical wound. Serial Focus 120 microPET images were obtained six hours post-tail vein injection of approximately 600 mu Ci of I-124-iodide. Results: Viral infectivity, measured by green fluorescent protein (GFP) expression, was time-and concentrationdependent. All cell lines showed less than 10% of cell survival five days after treatment at an MOI of 5. GLV-1h153 replicated efficiently in all cell lines with a peak titer of 27 million viral plaque forming units (PFU) ( < 10,000-fold increase from the initial viral dose) by Day 4. Administration of GLV-1h153 into the surgical wound allowed positive surgical margins to be identified via PET scanning. In vivo, mean volume of infected surgically resected residual tumors four weeks after treatment was 14 mm(3) versus 168 mm(3) in untreated controls (P < 0.05). Conclusions: This is the first study to our knowledge to demonstrate a novel vaccinia virus carrying hNIS as an imaging tool in identifying positive surgical margins of breast cancers in an orthotopic murine model. Moreover, our results suggest that GLV-1h153 is a promising therapeutic agent in achieving local control for positive surgical margins in resected breast tumors. KW - conservation KW - carcinoma KW - mastectomy KW - metastases KW - stage-i KW - thyroid-cancer KW - radiation-therapy KW - conserving surgery KW - sodium-iodide symporter Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-122140 VL - 15 IS - R26 ER - TY - THES A1 - Heß, Michael T1 - Vaccinia virus-encoded bacterial beta-glucuronidase as a diagnostic biomarker for oncolytic virotherapy T1 - Vaccinia Virus-codierte bakterielle Beta-Glucuronidase als diagnostischer Biomarker in der onkolytischen Virotherapie N2 - Oncolytic virotherapy represents a promising approach to revolutionize cancer therapy. Several preclinical and clinical trials display the safety of oncolytic viruses as wells as their efficiency against solid tumors. The development of complementary diagnosis and monitoring concepts as well as the optimization of anti-tumor activity are key points of current virotherapy research. Within the framework of this thesis, the diagnostic and therapeutic prospects of beta-glucuronidase expressed by the oncolytic vaccinia virus strain GLV-1h68 were evaluated. In this regard, a beta-glucuronidase-based, therapy-accompanying biomarker test was established which is currently under clinical validation. By using fluorescent substrates, the activity of virally expressed beta-glucuronidase could be detected and quantified. Thereby conclusions about the replication kinetics of oncolytic viruses in animal models and virus-induced cancer cell lysis could be drawn. These findings finally led to the elaboration and establishment of a versatile biomarker assay which allows statements regarding the replication of oncolytic viruses in mice based on serum samples. Besides the analysis of retrospective conditions, this test is able to serve as therapy-accompanying monitoring tool for virotherapy approaches with beta-glucuronidase-expressing viruses. The newly developed assay also served as complement to routinely used plaque assays as well as reference for virally expressed anti-angiogenic antibodies in additional preclinical studies. Further validation of this biomarker test is currently taking place in the context of clinical trials with GL-ONC1 (clinical grade GLV-1h68) and has already shown promising preliminary results. It was furthermore demonstrated that fluorogenic substrates in combination with beta-glucuronidase expressed by oncolytic viruses facilitated the optical detection of solid tumors in preclinical models. In addition to diagnostic purposes, virus-encoded enzymes could also be combined with prodrugs resulting in an improved therapeutic outcome of oncolytic virotherapy. In further studies, the visualization of virus-induced immune reactions as well as the establishment of innovative concepts to improve the therapeutic outcome of oncolytic virotherapy could be accomplished. In conclusion, the results of this thesis provide crucial findings about the influence of virally expressed beta-glucuronidase on various diagnostic concepts in the context of oncolytic virotherapy. In addition, innovative monitoring and therapeutic strategies could be established. Our preclinical findings have important clinical influence, particularly by the development of a therapy-associated biomarker assay which is currently used in different clinical trials. N2 - Onkolytische Viren stellen einen vielversprechenden Therapieansatz dar, der die Behandlung von Krebserkrankungen revolutionieren könnte. Intensive präklinische und klinische Studien zeigen sowohl die körperliche Verträglichkeit von onkolytischen Viren, als auch deren Wirksamkeit gegenüber soliden Tumoren. Die Entwicklung von therapiebegleitenden Diagnose- und Monitoringkonzepten sowie eine Optimierung der Antitumorwirkung onkolytischer Viren stellen Eckpunkte der aktuellen Forschung auf dem Gebiet der Virotherapie dar. Im Rahmen dieser Arbeit wurde untersucht, welche diagnostischen und therapeutischen Möglichkeiten die virale Expression von beta-Glucuronidase durch den onkolytischen Vaccinia-Virus-Stamm GLV-1h68 eröffnet. In diesem Zusammenhang wurde ein, auf beta-Glucuronidase basierender, therapiebegleitender Biomarkertest entwickelt, dessen klinische Validierung derzeit stattfindet. Mit Hilfe von fluorogenen Substraten konnte die Aktivität viral exprimierter beta-Glucuronidase detektiert und quantifiziert werden. Dies lies direkte Rückschlüsse auf das Replikationsverhalten von onkolytischen Viren im Tiermodell zu und ermöglichte zudem Aussagen über die Zelllyse Virus-infizierter Krebszellen. Diese Erkenntnisse führten letztendlich zur Ausarbeitung und Etablierung eines vielseitig anwendbaren Biomarker-Assays, der es ermöglicht anhand von Blutproben Aussagen über das Replikationsverhalten onkolytischer Viren in Mäusen zu machen. Neben retrospektiven Analysen erlaubt dieser Test auch ein therapiebegleitendes Monitoring der onkolytischen Virotherapie mit beta-Glucuronidase-exprimierenden Viren. In weiteren präklinischen Untersuchungen diente der entwickelte Assay zudem als Ergänzung zum viralen Plaque Assays sowie als Referenz für Virus-exprimierte anti-angiogene Antikörper. Eine fortführende Validierung dieses neuartigen Biomarkertests findet derzeit im Rahmen humaner Studien mit der klinischen Formulierung von GLV-1h68, GL-ONC1, statt und zeigte bereits erste positive Resultate. Weiterhin konnte im Rahmen dieser Arbeit gezeigt werden, dass die Expression von beta-Glucuronidase durch onkolytische Viren in Verbindung mit fluoreszierenden Substraten eine optische Detektion von Karzinomen im präklinischen Tiermodell ermöglicht. Neben diagnostischen Zwecken, konnten Virus-kodierte Enzyme in Kombination mit Prodrugs genutzt werden, um den Therapieerfolg der onkolytischen Virotherapie zu verbessern. In zusätzlichen Studien konnten zudem Methoden zur Visualisierung der Virus-induzierten Immunantwort sowie neuartige Konzepte zur Therapieverbesserung etabliert werden. Zusammenfassend liefern die Ergebnisse der vorliegenden Arbeit wichtige Erkenntnisse über den Einfluss Virus-exprimierter beta-Glucuronidase auf unterschiedliche Diagnosekonzepte im Rahmen der onkolytischen Virotherapie. Daneben konnten entscheidende Erkenntnisse über den möglichen Einsatz neuer Monitoring- und Therapieansätze erzielt werden. Insbesondere durch die Entwicklung eines therapiebegleitenden Biomarkertests haben diese Resultate erheblichen Einfluss auf die weitere klinische Anwendung von onkolytischen Vaccinia-Viren. KW - Vaccinia-Virus KW - Glucuronidase KW - Krebs KW - cancer KW - oncolytic virus KW - biomarker KW - beta-glucuronidase Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-86789 ER - TY - THES A1 - Huang, Ting T1 - Vaccinia Virus-mediated Therapy of Solid Tumor Xenografts: Intra-tumoral Delivery of Therapeutic Antibodies T1 - Vaccini-Virus-vermittelte Therapie solider Tumoren: Intra-tumoraler Transport therapeutischer Antikörper N2 - Over the past 30 years, much effort and financial support have been invested in the fight against cancer, yet cancer still represents the leading cause of death in the world. Conventional therapies for treatment of cancer are predominantly directed against tumor cells. Recently however, new treatments options have paid more attention to exploiting the advantage of targeting the tumor stroma instead. Vaccinia virus (VACV) has played an important role in human medicine since the 18th century as a vaccination against smallpox. In our laboratory, the recombinant, replication-competent vaccinia virus, GLV-1h68, was shown to enter, colonize and destroy cancer cells both in cell culture, and in vivo, in xenograft models (Zhang, Yu et al. 2007). In addition, combined therapy of GLV-1h68 and anti-VEGF immunotherapy significantly enhanced antitumor therapy in vivo (Frentzen, Yu et al. 2009). In this study, we constructed several new recombinant VACVs carrying genes encoding different antibodies against fibroblast activation protein (FAP) in stroma (GLV-1h282), nanobody against the extracellular domain of epidermal growth factor receptor (EGFR, GLV-1h442) or antibodies targeting both vascular endothelial growth factor (VEGF) and EGFR (GLV-1h444) or targeting both VEGF and FAP (GLV-1h446). The expression of the recombinant proteins was first verified using protein analytical methods, SDS-gel electrophoresis, Western blot analysis, immunoprecipitation (IP) assays and ELISA assays. The proteins were detected after infection of the cells with the different VACVs and the recombinant proteins purified by affinity adsorption. The purified antibodies were shown to specifically bind to their respective antigens. Secondly, the infection and replication capability of all the virus strains was analyzed in cell culture using several human tumor cell lines (A549, FaDu or DU145), revealing that all the new recombinant VACVs were able to infect cancer cells with comparable efficiency to the parental viruses from which they were derived. Thirdly, the antitumor efficacy of the new recombinant VACVs was evaluated in vivo using several human cancer xenograft models in mice. In A549 and DU145 xenografts, the new recombinant VACVs exhibited an enhanced therapeutic efficacy compared to GLV-1h68 with no change in toxicity in mice. In the FaDu xenograft, treatment with GLV-1h282 (anti-FAP) significantly slowed down the speed of tumor growth compared to GLV-1h68. Additionally, treatment with the recombinant VACVs expressed the various antibodies achieved comparable or superior therapeutic effects compared to treatment with a combination of GLV-1h68 and the commercial therapeutic antibodies, Avastin, Erbitux or both. Next, the virus distribution in tumors and organs of treated mice was evaluated. For most of the viruses, the virus titer in tumors was not signficantly diffferent than GLV-1h68. However, for animals treated with GLV-1h282, the virus titer in tumors was significantly higher than with GLV-1h68. This may be the reason for enhanced antitumor efficacy of GLV-1h282 in vivo. Lastly, the underlying mechanisms of therapeutic antibody-enhanced antitumor effects were investigated by immunohistochemistry. Blood vessels density and cell proliferation in tumors were suppressed after treatment with the antibody-encoded VACVs. The results indicated that the suppression of angiogenesis or cell proliferation in tumors may cause the observed therapeutic effect. In conclusion, the results of the studies presented here support the hypothesis that the treatment of solid tumors with a combination of oncolytic virotherapy and immunotherapy has an additive effect over each treatment alone. Moreover, expression of the immunotherapeutic antibody by the oncolytic VACV locally in the tumor enhances the antitumor effect over systemic treatment with the same antibody. Combined, these results indicate that therapy with oncolytic VACVs expressing-therapeutic antibodies may be a promising approach for the treatment of cancer. N2 - In den letzten 30 Jahren wurde viel Aufwand und finanzielle Unterstützung in den Kampf gegen Krebs investiert, doch das Resultat ist limitiert, da Krebs immer noch die zweithöchste Todesursache in der Welt darstellt. Zusätzlich zu gegenwärtig verwendeten Therapien, die vorwiegend gegen Tumorzellen gerichtet sind, wird neuen Therapien mehr Aufmerksamkeit gewidmet, die stattdessen direkt auf das Tumorstroma zielen. Onkolytische Vaccinia Viren haben seit dem 18ten Jahrhundert als Impfstoff gegen Pocken in der Humanmedizin eine wichtige Rolle gespielt. In unserem Labor hat das rekombinante, replikationskompetente Vaccinia Virus GLV-1h68 gezeigt, dass es in Zellkultur und in Xenograft Modellen in Krebszellen eindringen sowie diese kolonisieren und zerstören kann (Zhang, Yu et al. 2007). Zusätzlich verbessert die kombinierte Therapie von GLV-1h68 und anti-VEGF Immunotherapy signifikant die Antitumortherapie in vivo (Frentzen, Yu et al. 2009). In dieser Studie haben wir mehrere neue rekombinante VACVs konstruiert, die die Gene für verschiedene Antikörper gegen das Fibroblasten Aktivierungs Protein (FAP) im Stroma (GLV-1h282) oder einen Nanobody gegen die extrazelluläre Domäne des Epidermalen Wachstumsfaktor (EGFR; GLV-1h442) kodieren. Ausserdem wurden Viren konstruiert, die eine Ko-Expression von Antikörpern gegen sowohl vaskulären Endothelwachstumsfaktor (VEGF) als auch EGFR (GLV-1h444) oder gegen sowohl VEGF als auch FAP (GLV-1h446) erlauben. Zunächst wurden SDS-Gelelektrophorese, Western Blot Analyse, Immunprezipitation (IP) und ELISA Assays durchgeführt, um die Expression der rekombinanten Proteine in Zellen mit proteinanalytischen Methoden zu untersuchen. Die Proteine waren nach Infektion der Zellen mit den verschiedenen VACVs nachweisbar und wurden mittles des FLAG Tags mit einem IP Kit aufgereinigt. Es konnte gezeigt werden, dass die aufgereinigten Antikörper spezifisch an ihr jeweiliges Antigen binden. Zweitens wurde die Infektion und Replikationsfähigkeit aller Virusstämme in Zellkultur untersucht (A549, FaDu oder DU145) und mit ihrem jeweiligen Ausgangsstamm GLV-1h68, GLV-1h164, GLV-1h282 oder GLV-1h442 verglichen. Die Ergebnisse zeigten, dass alle neuen rekombinanten VACVs Zellen mit vergleichbarer Effizienz infizieren konnten wie ihre Ausgangsstämme. Drittens, um die Antitumoreffizienz der neuen rekombinanten Stämme in vivo zu testen, wurden verschiedene humane Tumor Xenotransplantat-tragende Nacktmäuse mit verschiedenen VACVs behandelt. In A549 und DU145 Xenotransplantaten zeigten die neuen rekombinanten VACVs erhöhte therapeutische Effizienz verglichen mit dem Ausgangsstamm GLV-1h68, ohne Veränderung der Toxizität in Mäusen. Im FaDu Xenotransplantat verursachte die Behandlung mit GLV-1h68 keine Tumorregression, wohingegen die Behandlung mit GLV-1h282 (anti-FAP) die Geschwindigkeit des Tumorwachstums signifikant verlangsamte sowie das Überleben verlängerte. Zusätzlich haben wir herausgefunden, dass die Behandlung mit Antikörpern, die mittels Virus geliefert wurden, einen identischen oder sogar erhöhten inhibitorischen Effekt erzielen können, wie in einer Kombinationstherapie von GLV-1h68 und kommerziell erhältlichen Antikörpern, wie Avastin, Erbitux oder beidem. Um die virale Verteilung in vivo zu untersuchen, wurden Tumore und Organe von Mäusen seziert und homogenisiert, gefolgt von Titration der Virusmenge. Die Virus-Titer in Tumoren waren signifikant höher in Tieren, die mit GLV-1h282 behandelt wurden als solche, die mit GLV-1h68 behandelt wurden. Dies mag den Grund für die erhöhte Antitumoreffizienz von GLV-1h282 in vivo darstellen. Die Virus-Titer in allen anderen Gruppen zeigten keinen signifikanten Unterschied. Um den Mechanismus der durch therapeutische Antikörper erhöhten Antitumortherapie zu untersuchen, wurde Immunohistochemie durchgeführt. Nach Behandlung mit den Antikörper-kodierenden VACVs waren die Blutgefäβdichte und Zellproliferation in Tumoren reduziert, nachgewiesen durch die jeweilige CD31 and Ki67 Färbung. Die Resultate deuteten an, dass die Suppression der Angiogenese oder der Zellproliferation in Tumoren den beobachteten Effekt verursachen könnte. Zusammenfassend zeigen die hier präsentierten Daten dass die Kombination der Behandlung von onkolytischer Virotherapie mit Immunotherapie durch Virus-gelieferte Antikörper einen vielversprechenden Ansatz für Krebstherapie darstellt. KW - Vaccinia-Virus KW - therapeutic antibody KW - oncolytic virus KW - Krebs KW - Therapie KW - Antikörper KW - Tumor Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-91327 ER - TY - THES A1 - Christ, Thomas T1 - Value-distribution of the Riemann zeta-function and related functions near the critical line T1 - Werteverteilung der Riemannschen Zetafunktion und verwandter Funktionen nahe der kritischen Geraden N2 - The Riemann zeta-function forms a central object in multiplicative number theory; its value-distribution encodes deep arithmetic properties of the prime numbers. Here, a crucial role is assigned to the analytic behavior of the zeta-function on the so called critical line. In this thesis we study the value-distribution of the Riemann zeta-function near and on the critical line. Amongst others we focus on the following. PART I: A modified concept of universality, a-points near the critical line and a denseness conjecture attributed to Ramachandra. The critical line is a natural boundary of the Voronin-type universality property of the Riemann zeta-function. We modify Voronin's concept by adding a scaling factor to the vertical shifts that appear in Voronin's universality theorem and investigate whether this modified concept is appropriate to keep up a certain universality property of the Riemann zeta-function near and on the critical line. It turns out that it is mainly the functional equation of the Riemann zeta-function that restricts the set of functions which can be approximated by this modified concept around the critical line. Levinson showed that almost all a-points of the Riemann zeta-function lie in a certain funnel-shaped region around the critical line. We complement Levinson's result: Relying on arguments of the theory of normal families and the notion of filling discs, we detect a-points in this region which are very close to the critical line. According to a folklore conjecture (often attributed to Ramachandra) one expects that the values of the Riemann zeta-function on the critical line lie dense in the complex numbers. We show that there are certain curves which approach the critical line asymptotically and have the property that the values of the zeta-function on these curves are dense in the complex numbers. Many of our results in part I are independent of the Euler product representation of the Riemann zeta-function and apply for meromorphic functions that satisfy a Riemann-type functional equation in general. PART II: Discrete and continuous moments. The Lindelöf hypothesis deals with the growth behavior of the Riemann zeta-function on the critical line. Due to classical works by Hardy and Littlewood, the Lindelöf hypothesis can be reformulated in terms of power moments to the right of the critical line. Tanaka showed recently that the expected asymptotic formulas for these power moments are true in a certain measure-theoretical sense; roughly speaking he omits a set of Banach density zero from the path of integration of these moments. We provide a discrete and integrated version of Tanaka's result and extend it to a large class of Dirichlet series connected to the Riemann zeta-function. N2 - Die Riemannsche Zetafunktion ist ein zentraler Gegenstand der multiplikativen Zahlentheorie; in ihrer Werteverteilung liegen wichtige arithmetische Eigenschaften der Primzahlen kodiert. Besondere Bedeutung kommt hierbei dem analytischen Verhalten der Zetafunktion auf der sog. kritischen Geraden zu. Wir untersuchen in dieser Arbeit die Werteverteilung der Riemannschen Zetafunktion auf und nahe der kritischen Geraden. Wir fokusieren wir uns dabei u.a. auf folgende Punkte. TEIL I: Ein modifiziertes Universalitätskonzept, a-Stellen nahe der kritischen Geraden und eine Dichtheitsvermutung nach Ramachandra. Die kritische Gerade fungiert als natürliche Grenze für die Voroninsche Universalitätseigenschaft der Riemannschen Zetafunktion. Wir modifizieren Voronins Universalitätskonzept dahingehend, dass wir die vertikalen Translationen aus Voronins Universalitätssatz mit einer zusätzlichen Skalierung versehen. Wir untersuchen, ob durch dieses modifizierte Konzept eine abgeschwächte Universalitätseigenschaft der Riemannschen Zetafunktion um die kritschen Gerade aufrecht erhalten werden kann. Es stellt sich heraus, dass die Gestalt der Funktionen, die sich auf diese Weise durch die Zetafunktion approximieren lassen, stark von der Funktionalgleichung und der Wahl des skalierenden Faktors abhängt. Nach einem Resultat von Levinson liegen fast alle a-Stellen der Riemannschen Zetafunktion in einem trichterförmigen Bereich um die kritische Gerade. Gewisse Normalitätsargumenten sowie das Konzept der 'filling discs' erlauben uns Levinsons Resultat zu ergänzen und a-Stellen in diesem trichterförmigen Bereich aufzuspüren, die sehr nahe an der kritischen Geraden liegen. Man vermutet, dass die Werte der Riemannschen Zetafunktion auf der kritischen Geraden dicht in den komplexen Zahlen liegen. Wir nähern uns dieser Vermutung (die man oft Ramachandra zuschreibt), indem wir die Existenz gewisser Kurven nachweisen, die sich asymptotisch an die kritische Gerade anschmiegen und die Eigenschaft besitzen, dass die Werte der Zetafunktion auf diesen Kurven dicht in den komplexen Zahlen liegen. Viele unserer Ergebnisse in Teil I sind unabhängig von der Eulerproduktdarstellung der Zetafunktion und gelten allgemein für beliebige meromorphe Funktionen, die einer Funktionalgleichung vom Riemann-Typ genügen. TEIL II: Diskrete und kontinuierliche Momente. Die Lindelöf Vermutung trifft eine Aussage über das Wachstumsverhalten der Zetafunktion auf der kritischen Geraden. Nach klassischen Arbeiten von Hardy und Littlewood lässt sie sich mittels Potenzmomente der Zetafunktion rechts von der kritischen Geraden umformulieren. Tanaka konnte kürzlich nachweisen, dass die asymptotischen Formeln, die man für diese Potenzmomente erwartet in einem gewissen maßtheoretischem Sinne Gülitgkeit besitzen: grob gesprochen wird heibei eine Menge mit Banachdichte null vom Integrationsweg der Potenzmomente ausgespart. Wir stellen eine diskrete und eine integrierte Version von Tanakas Resultat zur Verfügung. Zudem verallgemeinern wir Tanakas Ergebnis auf eine große Klasse von Dirichletreihen. KW - Riemannsche Zetafunktion KW - Riemann zeta-function KW - universality KW - a-point distribution Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-97763 ER - TY - JOUR A1 - Streng, Andrea A1 - Grote, Veit A1 - Carr, David A1 - Hagemann, Christine A1 - Liese, Johannes G. T1 - Varicella routine vaccination and the effects on varicella epidemiology – results from the Bavarian Varicella Surveillance Project (BaVariPro), 2006-2011 JF - BMC Infectious Diseases N2 - Background In 2004, routine varicella vaccination was recommended in Germany for children 11-14 months of age with one dose, and since 2009, with a second dose at 15-23 months of age. The effects on varicella epidemiology were investigated. Methods Data on varicella vaccinations, cases and complications were collected from annual parent surveys (2006-2011), monthly paediatric practice surveillance (Oct 2006 - Sep 2011; five varicella seasons) and paediatric hospital databases (2005-2009) in the area of Munich (about 238,000 paediatric inhabitants); annual incidences of cases and hospitalisations were estimated. Results Varicella vaccination coverage (1st dose) in children 18-36 months of age increased in two steps (38%, 51%, 53%, 53%, 66% and 68%); second-dose coverage reached 59% in the 2011 survey. A monthly mean of 82 (62%) practices participated; they applied a total of 50,059 first-dose and 40,541 second-dose varicella vaccinations, with preferential use of combined MMR-varicella vaccine after recommendation of two doses, and reported a total of 16,054 varicella cases <17 years of age. The mean number of cases decreased by 67% in two steps, from 6.6 (95%CI 6.1-7.0) per 1,000 patient contacts in season 2006/07 to 4.2 (95%CI 3.9-4.6) in 2007/08 and 4.0 (95%CI 3.6-4.3) in 2008/09, and further to 2.3 (95%CI 2.0-2.6) in 2009/10 and 2.2 (95%CI 1.9-2.5) in 2010/11. The decrease occurred in all paediatric age groups, indicating herd protection effects. Incidence of varicella was estimated as 78/1,000 children <17 years of age in 2006/07, and 19/1,000 in 2010/11. Vaccinated cases increased from 0.3 (95%0.2-0.3) per 1,000 patient contacts in 2006/07 to 0.4 (95%CI 0.3-0.5) until 2008/09 and decreased to 0.2 (95%CI 0.2-0.3) until 2010/11. The practices treated a total of 134 complicated cases, mainly with skin complications. The paediatric hospitals recorded a total of 178 varicella patients, including 40 (22.5%) with neurological complications and one (0.6%) fatality due to varicella pneumonia. Incidence of hospitalisations decreased from 7.6 per 100,000 children <17 years of age in 2005 to 4.3 in 2009, and from 21.0 to 4.7 in children <5 years of age. Conclusions Overall, the results show increasing acceptance and a strong impact of the varicella vaccination program, even with still suboptimal vaccination coverage. KW - Varicella KW - Surveillance KW - Coverage KW - Vaccination KW - Hospitalisation KW - Paediatric KW - Incidence Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-96297 UR - http://www.biomedcentral.com/1471-2334/13/303 ER - TY - JOUR A1 - Matlach, Juliane A1 - Freiberg, Florentina J. A1 - Gadeholt, Ottar A1 - Göbel, Winfried T1 - Vasculitis-like hemorrhagic retinal angiopathy in Wegener’s granulomatosis JF - BMC Research Notes N2 - Background: Granulomatosis with polyangiitis, also known as Wegener’s granulomatosis, is a chronic systemic inflammatory disease that can also involve the eyes. We report a case of massive retinal and preretinal hemorrhages with perivascular changes as the initial signs in granulomatosis with polyangiitis (Wegener’s granulomatosis). Case presentation: A 39-year-old Caucasian male presented with blurred vision in his right eye, myalgia and arthralgia, recurrent nose bleeds and anosmia. Fundus image of his right eye showed massive retinal hemorrhages and vasculitis-like angiopathy, although no fluorescein extravasation was present in fluorescein angiography. Laboratory investigations revealed an inflammation with increased C-reactive protein, elevated erythrocyte sedimentation rate and neutrophil count. Tests for antineutrophil cytoplasmic antibodies (ANCA) were positive for c-ANCA (cytoplasmatic ANCA) and PR3-ANCA (proteinase 3-ANCA). Renal biopsy demonstrated a focal segmental necrotizing glomerulonephritis. Granulomatosis with polyangiitis (Wegener’s granulomatosis) was diagnosed and a combined systemic therapy of cyclophosphamide and corticosteroids was initiated. During 3 months of follow-up, complete resorption of retinal hemorrhages was seen and general complaints as well as visual acuity improved during therapy. Conclusion: Vasculitis-like retinal changes can occur in Wegener’s granulomatosis. Despite massive retinal and preretinal hemorrhages that cause visual impairment, immunosuppressive therapy can improve ocular symptoms. KW - cyclophosphamide KW - Wegener’s granulomatosis KW - granulomatosis with polyangiitis KW - retinal vasculitis KW - hemorrhages Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-128744 VL - 6 IS - 364 ER - TY - JOUR A1 - Camago-Molina, J.E. A1 - O'Leary, B. A1 - Porod, W. A1 - Staub, F. T1 - Vevacious: a tool for finding the global minima of one-loop effective potentials with many scalars JF - European Physical Journal C N2 - Several extensions of the Standard Model of particle physics contain additional scalars implying a more complex scalar potential compared to that of the Standard Model. In general these potentials allow for charge- and/or color-breaking minima besides the desired one with correctly broken SU(2) L ×U(1) Y . Even if one assumes that a metastable local minimum is realized, one has to ensure that its lifetime exceeds that of our universe. We introduce a new program called Vevacious which takes a generic expression for a one-loop effective potential energy function and finds all the tree-level extrema, which are then used as the starting points for gradient-based minimization of the one-loop effective potential. The tunneling time from a given input vacuum to the deepest minimum, if different from the input vacuum, can be calculated. The parameter points are given as files in the SLHA format (though is not restricted to supersymmetric models), and new model files can be easily generated automatically by the Mathematica package SARAH. This code uses HOM4PS2 to find all the minima of the tree-level potential, PyMinuit to follow gradients to the minima of the one-loop potential, and CosmoTransitions to calculate tunneling times. KW - True Vacuum KW - One-loop Effective Potential KW - Saddle Point KW - Minimal Surface Tension KW - CMSSM Point KW - SM Gauge Group KW - Renormalization Scale KW - Landau Gauge KW - Homotopy Continuation Method KW - Gauge-dependent Quantity KW - False Vacuum KW - Spectrum Generator KW - SLHA File KW - Tunneling Time KW - Charged Scalar Field Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-132110 VL - 73 IS - 2588 ER -